Exclude Patient Type Detail Header
No
Footnote
<sup>1</sup> Anticoagulation thresholds suggested by such tools are not definitive indicators of requirement for anticoagulation [B].<br><br>
<sup>2</sup> Inform pt that stroke risk can potentially be reduced w/ antithrombotics but that major bleeding risk may ↑ [B]. Judgment/preferences play an important role in weighing potential risks/benefits [B].
<br><br>
<sup>3</sup> Risk-benefit ratio of oral anticoagulants is uncertain in pts w/ mod-severe dementia or very frequent falls [B]. Data are insufficient to determine whether anticoagulants are safe or effective in elderly pts who have frequent falls or advanced dementia. An elderly pt would need to fall 295 times in 1y to offset stroke-reduction benefits w/ warfarin.
<br><br>
<sup>4</sup> If pt well controlled, consider continuing warfarin vs switching to new oral anticoagulant [C].
<br><br>
<sup>5</sup> There are currently no clinical recommendations for the use of oral anticoagulants in NVAF w/ ESRD [U].
<sup>2</sup> Inform pt that stroke risk can potentially be reduced w/ antithrombotics but that major bleeding risk may ↑ [B]. Judgment/preferences play an important role in weighing potential risks/benefits [B].
<br><br>
<sup>3</sup> Risk-benefit ratio of oral anticoagulants is uncertain in pts w/ mod-severe dementia or very frequent falls [B]. Data are insufficient to determine whether anticoagulants are safe or effective in elderly pts who have frequent falls or advanced dementia. An elderly pt would need to fall 295 times in 1y to offset stroke-reduction benefits w/ warfarin.
<br><br>
<sup>4</sup> If pt well controlled, consider continuing warfarin vs switching to new oral anticoagulant [C].
<br><br>
<sup>5</sup> There are currently no clinical recommendations for the use of oral anticoagulants in NVAF w/ ESRD [U].
Detail Type
Text
Detail Text
Patient Type Detail Header (Long)
Use risk stratification scheme<sup>1</sup> to determine risk level